Navigation Links
Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
Date:5/30/2013

SOUTH SAN FRANCISCO, CA May 30, 2013 Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection. It is the only known nucleoside analog currently in clinical development for the treatment of RSV. ALS-8176 demonstrates potent anti-viral activity across multiple strains of RSV in preclinical studies and represents an important step forward in the development of more effective treatments for this serious and often life threatening disease.

The randomized, double-blind, placebo-controlled, Phase 1 study of orally administered ALS-8176 will evaluate safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses in healthy volunteers. The trial will assess several dose levels in up to 90 healthy adults.

ALS-8176 was discovered following the optimization of screening hits obtained through testing the Alios proprietary nucleoside analog library against replicating RSV in cell culture. The compound acts by blocking replication through a classic chain-termination mechanism and inhibits all RSV strains tested.

Due to their high barrier to viral resistance, nucleoside analogs have become the backbone of antiviral therapy in many clinical settings including the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpes simplex virus (HSV). More recently, emerging data suggest the pivotal role nucleoside analogs will play in the future treatment of chronic hepatitis C (HCV).

"Alios believes ALS-8176 has great potential to become an effective first-line antiviral therapy for RSV infection, a disease where few treatment options currently exist," said Lawrence M. Blatt, PhD, Chief Executive Officer. "The advancement of ALS-8176 for RSV, together with the recently repo
'/>"/>

Contact: John Donovan
press@aliosbiopharma.com
650-635-5504
Alios BioPharma, Inc.
Source:Eurekalert

Page: 1 2

Related biology news :

1. Exclusive agreement to distribute Affinity Biosensors Archimedes system extends Malvern Instruments biopharma solutions
2. Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies
3. Carnegie Mellon neuroscientists discover new phase of synaptic development
4. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
5. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
6. In beef production, cow-calf phase contributes most greenhouse gases
7. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
8. National Geographic unveils new phase of genographic project
9. King Richard III search in new phase after discovery has potential to rewrite history
10. Center for Clinical and Translational Science awards new pilot grants
11. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... about the way our bodies are assembled during early ... they are supposed to become a nerve or a ... correct place and alignment? Researchers at the University of ... a new study, UM researchers describe the signaling systems ... at the head-trunk region. Their discovery may have important ...
(Date:11/4/2014)... HOUSTON – (Nov. 4, 2014) – A majority of ... and that could have serious consequences for the rainforests ... researchers shows the positive impacts lemurs can have on ... impact their disappearance could have on the region,s rich ... rainforest have fruits eaten by lemurs. Lemurs in ...
(Date:11/3/2014)... of Colorado Cancer Center study published in ... Sciences describes the activity of a recently discovered ... or IL-37. It has been known to limit inflammation ... adaptive immune system: IL-37 inhibits the ability of the ... "Knowing this mechanism that underlies IL-37,s effect on the ...
Breaking Biology News(10 mins):The inside story: How the brain and skull stay together 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... adults living closer to a fast food restaurant had a ... away from fast food, according to researchers at The University ... particularly strong among those with a lower income. ... of Public Health indicates higher BMI associates with residential ...
... relationship between the heritable risk for schizophrenia and low ... associated with cognitive impairments that may cause functional disability. ... to the risk for developing schizophrenia. For example, reduced ... Also, these deficits may be present in healthy relatives ...
... hematopoiesis at sites outside the bone marrow in ... (LMU) in Munich now show that a specific type ... blood cells. Balanced hematopoiesis is essential for the ... takes place mainly in the liver and the spleen. ...
Cached Biology News:Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Genetic risk for schizophrenia is connected to reduced IQ 2Herpes infections: Natural killer cells activate hematopoiesis 2
(Date:11/21/2014)... York, NY (PRWEB) November 20, 2014 ... is now available as an open access journal featuring ... with infrared fluorescent proteins to preserve photoresponsiveness in the ... Two-color fluorescent in situ hybridization using chromogenic substrates ... chips for DNA, RNA, and protein electrophoresis , ...
(Date:11/21/2014)... 20, 2014 Polaris Group announced today ... its Phase 1 trial of ADI-PEG 20 in ... of malignant pleural mesothelioma (MPM) and non-squamous non-small ... trials on ADI-PEG 20, both as monotherapy and ... of several other indications, including breast cancer, melanomas, ...
(Date:11/18/2014)... 17, 2014 RPS Diagnostics (RPS®) ... – today announces its third annual partnership of ... Get Smart About Antibiotics Week from November 17-23. ... national campaign designed to highlight the coordinated efforts ... non-profit and for-profit partners to provide education about ...
(Date:11/18/2014)... 18, 2014 American Process Inc. ... formed a partnership with researchers at Georgia Institute ... Technology, and the USDA’s Forest Products Laboratory to ... nanocellulose. Nanocellulose is a rapidly emerging high performance ... project is to replace heavy steel structures within ...
Breaking Biology Technology:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3
... the platinum standard is, well, platinum! However, at about $2,000 ... cost of the raw material presents major challenges for the ... at the U.S. Department of Energy (DOE),s Lawrence Berkeley National ... these challenges is to think small really small. ...
... , ROME and NORWOOD, Mass. , ... Inc. presented new data this week demonstrating that the ... rates in single embryo transfer (SET) cycles for patients ... non-invasive procedure used to enhance in vitro ...
... June 28 Arteriocyte, Inc., was honored ... of Year Award Finalist. Founded in 2004 to develop ... focuses on developing commercially available stem cell based therapies ... peripheral cord blood, and cartilage) for delivery to injured ...
Cached Biology Technology:For platinum catalysts, smaller may be better 2For platinum catalysts, smaller may be better 3For platinum catalysts, smaller may be better 4Data Demonstrate ViaMetrics-E Improves Implantation Rates in Single Embryo Transfer IVF Cycles, A Growing Trend in Infertility Treatment 2Data Demonstrate ViaMetrics-E Improves Implantation Rates in Single Embryo Transfer IVF Cycles, A Growing Trend in Infertility Treatment 3Data Demonstrate ViaMetrics-E Improves Implantation Rates in Single Embryo Transfer IVF Cycles, A Growing Trend in Infertility Treatment 4Data Demonstrate ViaMetrics-E Improves Implantation Rates in Single Embryo Transfer IVF Cycles, A Growing Trend in Infertility Treatment 5Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010 2Arteriocyte Named Top Biotech Start Up Venture by the Ohio Venture Association for 2010 3
Guinea Pig Complement...
Collected from sexually matured, mixed breed, mixed sex guinea pigs....
Silica bead method is an economic method of DNA extraction from agarose...
...
Biology Products: